Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice.

Deng GM, Liu L, Tsokos GC.

Arthritis Rheum. 2010 Aug;62(8):2424-31. doi: 10.1002/art.27534.

2.

Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.

Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.

Arthritis Rheum. 2006 Oct;54(10):3277-83.

3.

Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway.

Deng GM, Liu L, Kyttaris VC, Tsokos GC.

J Immunol. 2010 Jun 15;184(12):7154-61. doi: 10.4049/jimmunol.0902514. Epub 2010 May 14.

4.

Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus.

Lian F, Wang Y, Chen J, Xu H, Yang X, Liang L, Zhan Z, Ye Y, Chen M.

Rheumatol Int. 2012 Jun;32(6):1705-10. doi: 10.1007/s00296-011-1874-2. Epub 2011 Mar 24.

PMID:
21431940
5.

PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.

Zhai JX, Zhang ZX, Feng YJ, Ding SS, Wang XH, Zou LW, Ye DQ.

Mol Biol Rep. 2012 Jun;39(6):6763-71. doi: 10.1007/s11033-012-1501-7. Epub 2012 Feb 9.

PMID:
22318546
6.

Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.

Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.

J Rheumatol. 2002 Apr;29(4):707-16.

PMID:
11950011
7.

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, Hodgin JB, Thompson PR, Kaplan MJ.

Ann Rheum Dis. 2015 Dec;74(12):2199-206. doi: 10.1136/annrheumdis-2014-205365. Epub 2014 Aug 7.

8.

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC.

Arthritis Rheum. 2010 Jul;62(7):2086-92. doi: 10.1002/art.27452.

9.

Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.

Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.

J Immunol. 2011 Sep 15;187(6):3413-21. doi: 10.4049/jimmunol.1101125. Epub 2011 Aug 17.

10.

Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.

Shimp SK 3rd, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CM.

Cell Mol Immunol. 2012 May;9(3):255-66. doi: 10.1038/cmi.2012.5. Epub 2012 Apr 30.

11.

Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus.

Racz Z, Nagy E, Rosivall L, Szebeni J, Hamar P.

Lupus. 2010 Apr;19(5):599-612. doi: 10.1177/0961203309355299. Epub 2010 Feb 18. Erratum in: Lupus. 2012 May;21(6):688.

PMID:
20167630
12.

Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.

Tada Y, Kondo S, Aoki S, Koarada S, Inoue H, Suematsu R, Ohta A, Mak TW, Nagasawa K.

Arthritis Rheum. 2011 Mar;63(3):738-48. doi: 10.1002/art.30183.

13.

Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice.

Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF.

J Immunol. 2006 Oct 15;177(8):5687-96.

14.

Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr/lpr mice is associated with increased local matrix metalloprotease activities.

Hedberg A, Fismen S, Fenton KA, Mortensen ES, Rekvig OP.

Exp Dermatol. 2010 Aug;19(8):e265-74. doi: 10.1111/j.1600-0625.2010.01064.x.

15.

Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, Putterman C.

J Autoimmun. 2013 Jun;43:44-54. doi: 10.1016/j.jaut.2013.03.002. Epub 2013 Apr 8.

16.
17.

Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?

Ballok DA, Sakic B.

Brain Behav Immun. 2008 Nov;22(8):1208-16. doi: 10.1016/j.bbi.2008.06.002. Epub 2008 Jun 14.

18.

Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).

Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R.

Eur J Pharmacol. 2013 Sep 5;715(1-3):230-7. doi: 10.1016/j.ejphar.2013.05.016. Epub 2013 May 24.

PMID:
23712004
19.

Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice.

Furukawa F, Kanauchi H, Wakita H, Tokura Y, Tachibana T, Horiguchi Y, Imamura S, Ozaki S, Takigawa M.

J Invest Dermatol. 1996 Jul;107(1):95-100.

20.

[Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].

Zhai ZF, Zhou CL, Zhong BY, Ao JH, Hao F.

Zhonghua Yi Xue Za Zhi. 2008 Feb 5;88(6):406-10. Chinese.

PMID:
18581896
Items per page

Supplemental Content

Write to the Help Desk